Cantacuzino Institute set to restart production of vaccines in two years

Romanian Cantacuzino Institute will be able to restart production of vaccines in about two-three years, Defense Minister Mihai Fifor announced during a conference on the future of this institution.

Mihai Fifor: We will relaunch the production of flu vaccine, we will relaunch the BCG (vaccine against tuberculosis, n.a.) and at the same time we want to return to the well-known brands of the Cantacuzino Institute, like the famous anti-flu vaccine Polidin used for years by Romanians or Canesten, another branded product of the Cantacuzino Institute, as well as to products that are to be developed through research in the Cantacuzino Institute. Most optimistic timeline for re-marketing the flu vaccine is one and a half year or two years.

Mihai Fifor added that at the Cantacuzino Institute will advertise about 200 jobs.

Romanian Cantacuzino National Institute of Research-Development for Microbiology and Immunology (CNIR) performs scientific research and delivers training in the fields of microbiology, immunology, epidemiology, molecular biology and genetics. Despite ranking among the most appreciated immunological producers in the world, the Institute has started to face decline since February 2010, after the National Agency of Medicines withdrew its authorization to sell products for injection, including vaccines, as the fabrication standard had expired. Under these conditions, some immunization national programs have been blocked for several months, and the authorities have had to import other vaccines.

Cantacuzino Institute has been under the successive jurisdiction of the National Authority for Scientific Research and Innovation,the Health Ministry and, from the end of 2017, the Ministry of Defense.

Source:RRA.Translated by Miruna Matei